Open Access
Issue
Med Sci (Paris)
Volume 36, Number 4, Avril 2020
Page(s) 389 - 393
Section Repères
DOI https://doi.org/10.1051/medsci/2020059
Published online 01 May 2020
  1. High KA, Roncarolo MG. Gene Therapy. N Engl J Med 2019 ; 381 : 455–464. [Google Scholar]
  2. Fischer A, Hacein-Bey-Abina S. Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med 2020; 217 : e20190607. [CrossRef] [PubMed] [Google Scholar]
  3. Editorial. Gene therapy’s next installment. Nat Biotechnol 2019; 37 : 697. [CrossRef] [PubMed] [Google Scholar]
  4. Bach PB. National coverage analysis of CAR-T therapies - Policy, evidence, and payment. N Engl J Med 2018 ; 379 : 1396–1398. [Google Scholar]
  5. Mazzucato M.. High cost of new drugs. BMJ 2016 ; 354 : i4136. [Google Scholar]
  6. Fischer A, Dewatripont M, Goldman M. Benefit corporation: a path to affordable gene therapies?. Nat Med 2019 ; 25 : 1813–1814. [CrossRef] [PubMed] [Google Scholar]
  7. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med 2019 ; 381 : 1809–1819. [Google Scholar]
  8. Collins FS. Realizing the dream of molecularly targeted therapies for cystic fibrosis. N Engl J Med 2019 ; 381 : 1863–1865. [Google Scholar]
  9. Bach PB. Anchoring’ was at work in setting the price of Novartis’ new gene therapy. https://www.statnews.com/2019/2006/2004/anchoring-price-zolgensma/. June 4, 2019. [Google Scholar]
  10. Evaluate Pharma. World Preview 2019, Outlook to 2024 (2019). https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024. [Google Scholar]
  11. Stevens AJ, Jensen JJ, Wyller K, et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011 ; 364 : 535–541. [Google Scholar]
  12. Nayak RK, Avorn J, Kesselheim AS. Public sector financial support for late stage discovery of new drugs in the United States: cohort study. BMJ 2019 ; 367 : l5766. [Google Scholar]
  13. Sarpatwari A, LaPidus AK, Kesselheim AS. Revisiting the National institutes of health fair pricing condition: promoting the affordability of drugs developed with government support. Ann Intern Med 2020. [Google Scholar]
  14. World Health Organization. Improving the transparency of markets for medicines, vaccines, and other health products. SEVENTY-SECOND WORLD HEALTH ASSEMBLY72/A/CONF./2 Rev. 1 Agenda item 11.7; 28 May 2019: https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf. [Google Scholar]
  15. Luzzatto L, Hyry HI, Schieppati A, et al. Outrageous prices of orphan drugs: a call for collaboration. Lancet 2018 ; 392 : 791–794. [CrossRef] [PubMed] [Google Scholar]
  16. Green A. Biotech companies defend prices of one-off gene therapy. Financial Times https://www.ft.com/content/edd639fc-9755-11e9-98b9-e38c177b152f: December 9, 2019. [Google Scholar]
  17. New York University Stern school of business. httpi//bit.ly/2IIHwZw. [Google Scholar]
  18. Thakor RT, Anaya N, Zhang Y, et al. Just how good an investment is the biopharmaceutical sector?. Nat Biotechnol 2017 ; 35 : 1149–1157. [CrossRef] [PubMed] [Google Scholar]
  19. Tay-Teo K, Ilbawi A, Hill SR. Comparison of sales income and research and development costs for FDA-approved cancer drugs sold by originator drug companies. JAMA Netw Open 2019 ; 2 : e186875. [Google Scholar]
  20. Bolton P, Dewatripont M. Contract theory. Cambridge : The MIT Press, 2004. [Google Scholar]
  21. Hart O. Firms, contracts, and financial structure. Clarendon Press-Oxford University Press, 1995. [CrossRef] [Google Scholar]
  22. Wineinger NE, Zhang, Topol EJ. Trends in prices of popular brand-name prescription drugs in the United States. JAMA Netw Open 2019; 2 : e194791. [Google Scholar]
  23. La Cour des Comptes. Le rapport public annuel 2017. https://www.ccomptes.fr/fr/publications/le-rapport-public-annuel-2017. 8 février 2017. [Google Scholar]
  24. Marsden G, Towse A, Pearson SD, et al. Gene therapy: understanding the science, assessing the evidence, and paying for value. ICER - Institute for clinical and economic review, a report from the 2016 ICER membership policy. March 2017. [Google Scholar]
  25. Business rountable. Our commitment. https://opportunity-businessrountable.org/ ourcommitment. Released: 2019; signatures updated: September 2019, December 2019, February 2020. [Google Scholar]
  26. Cummings B.. Benefit corporations : how to enforce a mandate to promote the public interest. Columbia Law Rev 2012 ; 112 : 578–627. [Google Scholar]
  27. DNDi - Drugs for Neglected Disease Initiative. https://dndi.org. [Google Scholar]
  28. Nielsen TB, Brass EP, Gilbert DN, et al. Sustainable discovery and development of antibiotics - Is a nnonprofit approach the future?. N Engl J Med 2019 ; 381 : 503–505. [Google Scholar]
  29. Barkats M. SMA: de la découverte du gène à la thérapie génique. Med Sci (Paris) 2020; 36 : 137–40. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  30. Braun S. Thérapies génétiques de l’amyotrophie spinale infantile : un morceau d’histoire de la médecine. Med Sci (Paris) 2020; 36 : 141–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  31. Pécoul B.. Un modèle alternatif et innovant de recherche et développement pour garantir l’accès aux médicaments. Maladies négligées, populations négligées et système d’innovation biomédicale. Med Sci (Paris) 2016 ; 32 : 1049–1050. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.